The company in partnership with the University of Edinburgh recently completed a trial of the test involving 400 patients.
VALUE-Dx involves six IVD companies and is being heralded by participants as an opportunity for competitors to work together to improve test adoption.
While the first task of the centers will be to digitize their workflows to improve efficiency, they also aim to eventually develop new AI-based analytical tools for diagnosing patients.
The institutes will lead a program investigating antimicrobial resistance in India and developing new diagnostic technologies to support antibiotic stewardship.
Three independent studies have shown that an α-synuclein assay technology detected early Parkinson's with high levels of sensitivity and specificity.
The model aims to uncover stroke patients at high, medium, or low risk of cerebral amyloid angiopathy, which is linked to additional strokes or dementia.
A combined biomarker model was more sensitive and specific than a standard test in identifying patients with liver injury after overdosing on paracetamol.